Brief: Vertex Pharmaceuticals Q1 Revenue USD 2,760.2 Million Vs. IBES Estimate USD 2,853 Million
05/05/2025 21:01
May 05 (Reuters) - Vertex Pharmaceuticals Q1 pretax profit USD 730.4 million vs. IBES estimate USD 1,368 million. Q1 adjusted operating income USD 1,183 million vs. IBES estimate USD 1,254 million Q1 adjusted net income USD 1,100 million vs. IBES estimate USD 1,134 million Q1 operating income USD 630.1 million Q1 net income USD 646.3 million OUTLOOK FY TOTAL REVENUE USD 11,850-12,000 MILLION
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31